Cressets New Activity Miner for Lead Optimization Highlights and Explains Key Activity Insights
Cresset announces the release of the Activity Miner module for Torch and Forge. Activity Miner is a new intuitive SAR interpretation tool that identifies the key 3D structural and electrostatic changes impacting biological activity.
Activity Miner employs new science to calculate and compare the structural and activity differences between each pair of molecules in a dataset. The intuitive visualisation tools make it easy to understand why a specific change resulted in improved activity, and to understand those cases where an apparently large change in chemistry results in a very small change in activity.
“The optimisation path of a compound through a design cycle is usually stepwise. Small structural changes usually result in small activity changes. The exceptions, when a small change of structure or electrostatics results in a large change in activity, are known as activity cliffs,” explains Dr Robert Scoffin, CEO of Cresset.
“Not only does Activity Miner locate these activity cliffs, it also helps researchers understand their causes. Previous approaches such as matched molecular pairs (MMP) analysis have relied solely upon 2D structural differences. Although this can explain many situations, it will miss others. Activity Miner uses 3D shape and electrostatic information, as well as 2D structural information, so researchers can get to the root causes of activity changes.”
Activity Miner is available as a module in Cresset’s Torch and Forge software suites.
Related News
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News AbbVie secures GBP£1.2 billion deal for Gilgamesh’s psychedelic programme
AbbVie has penned a significant agreement to acquire the bretisilocin programme from Gilgamesh Pharmaceuticals for up to £1.2 billion, marking a bold step in the pharmaceutical giant's quest to develop treatments for psychiatric disorders. -
News Gates Foundation commits US$2.5 billion to women’s health research
The Bill & Melinda Gates Foundation has announced a substantial US$2.5 billion commitment to accelerate research and development focused exclusively on women's health through 2030.
-
News Mid-year review: notable FDA drug approvals of 2025
As we fly past the halfway point of 2025, the pharmaceutical landscape reliably continues to evolve with innovative therapies addressing critical medical needs. The FDA has already approved 17 groundbreaking medications this year, each representin... -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.